



Supplementary Figure S1. Schematic overview of treatment for childhood classical Hodgkin Lymphoma according to the EuroNet-PHL-C2 protocol.

Textual description of the treatment-flow: All patients are assigned to a treatment level at time of diagnosis based on their stage of disease and presence of risk factors. All patients receive 2x OEPA induction chemotherapy courses. Consolidation treatment depends on treatment level and early treatment response (determined by PET-CT). TL1 patients receive 1x COPDAC-28 in case of adequate treatment response, or involved node radiotherapy in case of inadequate treatment response. TL2 and TL3 patients are randomized to either receive standard COPDAC-28 consolidation or intensified DECOPDAC-21 consolidation. Number of consolidation courses depends on assigned treatment level. TL2 patients receive two courses, TL3 patients receive four courses. Indication for radiotherapy depends on treatment response and randomization result. TL2/3 COPDAC-28 patients receive radiotherapy to all initially involve sites with 20 Gy with an additional 10 Gy boost to all PET positive sites on the late response assessment PET-scan. TL2/3 DECOPDAC-21 patients only receive radiotherapy to LRA PET-positive sites (30 Gy). TL, treatment level; OEPA, vincristine, etoposide, prednisone, doxorubicin; ERA; early response assessment; AR, adequate response (=complete remission); IR, inadequate response (=incomplete remission); COPDAC-28, cyclophosphamide, vincristine, prednisone, and dacarbazine; DECOPDAC-21, doxorubicin, etoposide, cyclophosphamide, vincristine, prednisone, and dacarbazine, LRA; late response assessment, RT; radiotherapy, Gy; gray.